PureTech Health (LON:PRTC) Hits New 1-Year Low – Here’s Why

PureTech Health plc (LON:PRTC) shares hit a new 52-week low during mid-day trading on Friday. The company traded as low as GBX 107.20 and last traded at GBX 107.80, with a volume of 847011 shares. The stock had previously closed at GBX 110.60.

Wall Street Analysts Forecast Growth

Separately, Peel Hunt reiterated a “buy” rating and issued a GBX 508 price target on shares of PureTech Health in a research report on Monday, July 13th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of GBX 508.

PureTech Health Trading Down 2.5%

The company has a debt-to-equity ratio of 4.78, a current ratio of 4.60 and a quick ratio of 2.51. The firm has a market cap of £264.30 million, a price-to-earnings ratio of -2.34 and a beta of 0.77. The business’s 50-day moving average price is GBX 119.36 and its two-hundred day moving average price is GBX 123.60.

Insider Buying and Selling

In other PureTech Health news, insider Sharon Barber-Lui purchased 93,944 shares of PureTech Health stock in a transaction on Wednesday, July 29th. The shares were bought at an average price of GBX 1 per share, with a total value of £939.44. Also, insider Kiran Mazumdar Shaw acquired 93,944 shares of the stock in a transaction dated Wednesday, July 29th. The stock was acquired at an average cost of GBX 1 per share, with a total value of £939.44. Insiders acquired a total of 617,569 shares of company stock worth $18,063,751 in the last three months. 13.41% of the stock is currently owned by insiders.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.